Policy changes in opioid agonist therapy and impacts on HIV and hepatitis C prevention in Canadian federal prisons

This publication has 8 references indexed in Scilit:

• Gatekeeping harm reduction in Canadian Federal Prisons: Perspectives on the threat risk assessment for the prison needle exchange program by prison administrative leadership
  Addiction, 2026
• Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States
  International Journal of Drug Policy, 2025
• Trends in injectable buprenorphine prescribing in Canada: A descriptive analysis in five Canadian Provinces
  Drug and Alcohol Dependence, 2024
• Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine
  Health & Justice, 2024
• Rates and causes of death after release from incarceration among 1 471 526 people in eight high-income and middle-income countries: an individual participant data meta-analysis
  The Lancet, 2024
• Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study
  BMC Public Health, 2022
• Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
  JAMA Network Open, 2021
• Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence
  JAMA Psychiatry, 2021